Vaxcyte (PCVX) Accumulated Expenses (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Accumulated Expenses of $30.2 million for Q1 2026, up 16.15% year-over-year from $26.0 million in Q1 2025, and down 2.64% quarter-over-quarter from $31.1 million in Q4 2025.
Vaxcyte (PCVX) Accumulated Expenses (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Accumulated Expenses for 8 consecutive years, with $30.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 16.15% year-over-year to $30.2 million; the TTM figure through Mar 2026 stood at $30.2 million (up 16.15% YoY), while the FY2025 annual figure was $31.1 million, up 6.68% from the prior year.
- Accumulated Expenses fell to $30.2 million in Q1 2026 per PCVX's latest filing, from $31.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $54.2 million in Q1 2024 and bottomed at $4.4 million in Q2 2023.
- Historically, Accumulated Expenses has averaged $19.6 million across 5 years, with a median of $15.4 million in 2022.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 602.2% — and 2023, when it tumbled 55.37%.
- Vaxcyte's Accumulated Expenses stood at $15.4 million in 2022, then declined by 28.09% to $11.1 million in 2023, then soared by 163.41% to $29.1 million in 2024, then gained by 6.68% to $31.1 million in 2025, then declined by 2.64% to $30.2 million in 2026.
- Business Quant data shows PCVX's Accumulated Expenses at $30.2 million in Q1 2026, $31.1 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.73 Mn |
| Mar 31, 2026 | 30.25 Mn |
| Dec 31, 2025 | 31.07 Mn |
| Sep 30, 2025 | 16.76 Mn |
| Jun 30, 2025 | 32.21 Mn |
| Mar 31, 2025 | 26.04 Mn |
| Dec 31, 2024 | 29.12 Mn |
| Sep 30, 2024 | 12.24 Mn |
| Jun 30, 2024 | 6.46 Mn |
| Mar 31, 2024 | 54.17 Mn |
| Dec 31, 2023 | 11.06 Mn |
| Sep 30, 2023 | 15.02 Mn |
| Jun 30, 2023 | 4.42 Mn |
| Mar 31, 2023 | 18.35 Mn |
| Dec 31, 2022 | 15.38 Mn |
| Sep 30, 2022 | 13.68 Mn |
| Jun 30, 2022 | 9.89 Mn |
| Mar 31, 2022 | 7.74 Mn |
| Dec 31, 2021 | 8.79 Mn |
| Sep 30, 2021 | 12.03 Mn |